{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:14Z","timestamp":1787021414784,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1245\/s10434-019-08139-4","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T13:02:28Z","timestamp":1576155748000},"page":"2539-2547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series"],"prefix":"10.1245","volume":"27","author":[{"given":"Joshua C.","family":"Leinwand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Chabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"issue":"5","key":"8139_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/02656736.2017.1320591","volume":"33","author":"KK Turaga","year":"2017","unstructured":"Turaga KK, Deraco M, Alexander HR. Current management strategies for peritoneal mesothelioma. Int J Hyperthermia. 2017;33(5):579\u201381.","journal-title":"Int J Hyperthermia."},{"issue":"6","key":"8139_CR2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1245\/s10434-010-1042-z","volume":"17","author":"PH Sugarbaker","year":"2010","unstructured":"Sugarbaker PH. Five Reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17(6):1710\u20132.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"8139_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11864-011-0151-7","volume":"12","author":"KM Turner","year":"2011","unstructured":"Turner KM, Varghese S, Alexander HR Jr. Surgery for peritoneal mesothelioma. Curr Treat Opt Oncol. 2011;12(2):189\u2013200.","journal-title":"Curr Treat Options Oncol."},{"issue":"9","key":"8139_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/14737140.2016.1220305","volume":"16","author":"JC Leinwand","year":"2016","unstructured":"Leinwand JC, Chabot JA, Kluger MD. Preventing recurrence of diffuse malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2016;16(9):989\u201395.","journal-title":"Expert Rev Anticancer Ther."},{"issue":"4","key":"8139_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jso.21055","volume":"98","author":"M Deraco","year":"2008","unstructured":"Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98(4):268\u201372.","journal-title":"J Surg Oncol."},{"issue":"5","key":"8139_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827\u201334.","journal-title":"Ann Oncol."},{"issue":"2","key":"8139_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.lungcan.2009.08.007","volume":"66","author":"A Saxena","year":"2009","unstructured":"Saxena A, Chua TC. Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma. Lung Cancer. 2009;66(2):269\u201370.","journal-title":"Lung Cancer."},{"key":"8139_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander Jr","year":"2013","unstructured":"Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779\u201386.","journal-title":"Surgery."},{"issue":"36","key":"8139_CR9","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342.","journal-title":"J Clin Oncol."},{"issue":"10","key":"8139_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ejso.2010.07.001","volume":"36","author":"MD Kluger","year":"2010","unstructured":"Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol. 2010;36(10):997\u20131003.","journal-title":"Eur J Surg Oncol."},{"issue":"6","key":"8139_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ejso.2006.03.009","volume":"32","author":"R Garcia-Carbonero","year":"2006","unstructured":"Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):676\u201381.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"8139_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","volume":"7","author":"PA J\u00e4nne","year":"2005","unstructured":"J\u00e4nne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40\u20136.","journal-title":"Clin Lung Cancer."},{"issue":"5","key":"8139_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3816\/CLC.2003.n.009","volume":"4","author":"W Schutte","year":"2003","unstructured":"Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, Treutler D, Schneider CP, Bonner R. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer. 2003;4(5):294\u20137.","journal-title":"Clin Lung Cancer."},{"issue":"2","key":"8139_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Malignant peritoneal mesothelioma\u2014results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64(2):211\u20138.","journal-title":"Lung Cancer."},{"issue":"1","key":"8139_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.rmed.2009.07.019","volume":"104","author":"M Reck","year":"2010","unstructured":"Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. Respir Med. 2010;104(1):142\u20138.","journal-title":"Respir Med."},{"issue":"24","key":"8139_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1200\/JCO.2010.29.1039","volume":"28","author":"M Markman","year":"2010","unstructured":"Markman M. Continued uncertainty regarding hyperthermic intraperitoneal chemotherapy in malignant peritoneal mesothelioma. J Clin Oncol. 2010;28(24):e418.","journal-title":"J Clin Oncol."},{"key":"8139_CR17","first-page":"153","volume":"134","author":"M Markman","year":"2007","unstructured":"Markman M. Current status of intraperitoneal antineoplastic drug delivery. Cancer Treat Res. 2007;134:153\u201369.","journal-title":"Cancer Treat Res."},{"issue":"5","key":"8139_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1245\/s10434-007-9768-y","volume":"15","author":"DL Bartlett","year":"2008","unstructured":"Bartlett DL. HIPEC: the complexities of clinical trials. Ann Surg Oncol. 2008;15(5):1277\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"8139_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COC.0b013e3180684181","volume":"31","author":"ME Hesdorffer","year":"2008","unstructured":"Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31(1):49\u201354.","journal-title":"Am J Clin Oncol."},{"key":"8139_CR20","unstructured":"Malignant mesothelioma: Number of deaths by sex, race, age group, and median age at death, U.S. residents age 15 and over, 2005\u20132014. Mortality multiple cause-of-death data from National Center for Health Statistics, National Vital Statistics System. https:\/\/wwwn.cdc.gov\/eworld\/Data\/897. Accessed 29 Aug 2019."},{"issue":"11","key":"8139_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 201;5(11):236.","journal-title":"Ann Transl Med."},{"issue":"2","key":"8139_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1245\/s10434-006-9187-5","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma\u2014a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14(2):515\u201325.","journal-title":"Ann Surg Oncol."},{"key":"8139_CR23","doi-asserted-by":"crossref","unstructured":"Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23(6):1494\u20138.","DOI":"10.1093\/annonc\/mdr477"},{"key":"8139_CR24","doi-asserted-by":"crossref","unstructured":"Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011;117(9):1855\u201363.","DOI":"10.1002\/cncr.25640"},{"key":"8139_CR25","doi-asserted-by":"publisher","first-page":"2782590","DOI":"10.1155\/2017\/2782590","volume":"2017","author":"R Shavelle","year":"2017","unstructured":"Shavelle R, Vavra-Musser K, Lee J, Brooks J. Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017;2017:2782590.","journal-title":"Lung Cancer Int."},{"issue":"24","key":"8139_CR26","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560\u20137.","journal-title":"J Clin Oncol."},{"issue":"10","key":"8139_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/JTO.0b013e31815608d9","volume":"2","author":"RM Flores","year":"2007","unstructured":"Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2(10):957\u201365.","journal-title":"J Thorac Oncol."},{"issue":"2","key":"8139_CR28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","volume":"105","author":"SA Saddoughi","year":"2018","unstructured":"Saddoughi SA, Abdelsattar ZM, Blackmon SH. National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study. Ann Thorac Surg. 2018;105(2):432\u20137.","journal-title":"Ann Thorac Surg."},{"key":"8139_CR29","doi-asserted-by":"crossref","unstructured":"Letica-Kriegel AS, Leinwand JC, Sonett JR, Gorenstein LA, Taub RN, Chabot JA, Kluger MD. 50 Patients with malignant mesothelioma of both the pleura and peritoneum: a single-institution experience. Ann Surg Oncol. 2019.","DOI":"10.1245\/s10434-019-07409-5"},{"issue":"13","key":"8139_CR30","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1245\/s10434-017-6106-x","volume":"24","author":"DR Heller","year":"2017","unstructured":"Heller DR, Chiuzan C, Taub RN, Leinwand JC, Greene AM, Bates GE, Chabot JA, Kluger MD. Recurrence of optimally treated malignant peritoneal mesothelioma with cytoreduction and heated intraperitoneal chemotherapy. Ann Surg Oncol. 2017;24(13):3818\u201324.","journal-title":"Ann Surg Oncol."},{"key":"8139_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1245\/s10434-008-0219-1","volume":"16","author":"D Baratti","year":"2009","unstructured":"Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009;16:463\u201372.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"8139_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ejso.2015.07.004","volume":"41","author":"Y Huang","year":"2015","unstructured":"Huang Y, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2015;41(10):1373\u201378.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"8139_CR33","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1245\/s10434-013-3341-7","volume":"21","author":"J Wong","year":"2014","unstructured":"Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014;21(5):1480\u201386.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"8139_CR34","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","volume":"22","author":"C Ihemelandu","year":"2015","unstructured":"Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22(5):1680\u201385.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"8139_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1245\/s10434-012-2790-8","volume":"20","author":"JC Leinwand","year":"2013","unstructured":"Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN. Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1101\u20134.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"8139_CR36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/000313481408000415","volume":"80","author":"SJ Shetty","year":"2014","unstructured":"Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg. 2014;80(4):348\u201352.","journal-title":"Am Surg."},{"issue":"5","key":"8139_CR37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686\u201393.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"8139_CR38","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228\u201335.","journal-title":"Eur J Surg Oncol."},{"issue":"Suppl 3","key":"8139_CR39","doi-asserted-by":"publisher","first-page":"S553","DOI":"10.1245\/s10434-013-2976-8","volume":"20","author":"JC Leinwand","year":"2013","unstructured":"Leinwand JC, Zhao B, Guo X, Krishnamoorthy S, Qi J, Graziano JH, Slavkovic VN, Bates GE, Lewin SN, Allendorf JD, Chabot JA, Schwartz LH, Taub RN. Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(Suppl 3):S553\u20139.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08139-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-08139-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08139-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T20:09:48Z","timestamp":1607630988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-08139-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["8139"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-08139-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}